+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy



Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy



European Journal of Cancer 56: 85-92



In resource-constrained environments many patients with human epidermal growth factor receptor 2 (HER2)+ early breast cancer are currently not offered adjuvant anti-HER2 therapy. For patients who might be able to receive the tyrosine kinase inhibitor (TKI) lapatinib (e.g. after patent expiration), it is important to identify subgroups of patients for whom anti-HER2 TKI therapy could be beneficial. To do this, we used data from 2489 patients with centrally confirmed HER2+ disease enrolled in the adjuvant Tykerb Evaluation After Chemotherapy (TEACH) trial, investigating the effect of lapatinib in patients with HER2+ early breast cancer not treated with trastuzumab. We performed subgroup analyses and number-needed-to-treat (NNT) calculations using patient and tumour associated predictors. Hormone receptor negative (HR-) patients on lapatinib had a significantly prolonged disease-free survival (DFS) compared to HR- patients on placebo (hazard ratio 0.64, P=0.003). For patients with HR- disease, starting treatment with lapatinib ≤1 year from diagnosis improved DFS by 12.1% [2.1-22.1] at 2 years and 15.7% [4.1-27.2] at 5 years. Depending on lymph node status and time since diagnosis the NNT for recurrence (at 5 years) was between 5.9 (node positive patients <1 year from diagnosis) and 15.9. These numbers are in range with numbers reported for up-front adjuvant trastuzumab for HR unselected patients (e.g. 15.6 for DFS at 4 years in HERA). In a subgroup analysis of the adjuvant TEACH trial, we show that anti-HER2 monotherapy with a TKI is beneficial as adjuvant therapy in a subgroup of patients. NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials.

(PDF emailed within 0-6 h: $19.90)

Accession: 058039165

Download citation: RISBibTeXText

PMID: 26829011

DOI: 10.1016/j.ejca.2015.12.024


Related references

Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report. Future Oncology 11(15 Suppl): 9-15, 2016

Identification of a 6 gene molecular predictor of lapatinib related benefit: From breast cancer cell lines to a phase III trial. Journal of Clinical Oncology 26(15_suppl): 1043-1043, 2016

Lapatinib: new directions in HER2 directed therapy for early stage breast cancer. Cancer Treatment and Research 151: 197-215, 2010

Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe. Onkologie 34(5): 233-238, 2011

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. Netherlands Journal of Medicine 68(9): 371-376, 2011

Variation in early breast cancer systemic adjuvant therapy practice among UK oncologists with potential impact on patient benefit and the financial burden: national postal questionnaire survey. Clinical Oncology ) 21(9): 734-735, 2010

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Research and Treatment 138(2): 427-435, 2013

A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. Investigational New Drugs 30(5): 1972-1977, 2013

High lapatinib plasma levels in breast cancer patients: risk or benefit?. Tumori 98(1): 162-165, 2012

An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). Annals of Oncology 24(4): 924-930, 2013

Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation. International Journal of Radiation Oncology, Biology, Physics 88(2): 274-284, 2014

Lapatinib in second-line treatment for metastatic breast cancer: rapid clinical benefit and long-term response. Tumori 99(6): 261e-263e, 2014

Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Tumori 99(6): 269e-272e, 2014

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology 34(10): 1034-1042, 2016

Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?. Journal of the National Cancer Institute. Monographs: 146-152, 2002